Last updated: 2026-10-12 09:03:00. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Becton, Dickinson and Co. (BDX) operates in the SURGICAL & MEDICAL INSTRUMENTS & APPARATUS sector and is listed on NYSE. The stock is currently priced at $183,77, with a market capitalisation of $50,05B and a P/E ratio of 53,19. Over the past 52 weeks, its price has ranged from $140,11 to $213,08. This page covers its latest market performance, valuation, price trends and company information.
$50,05B | |
$183,50 | |
$287,32 | |
$34,10 | |
$183,75 | |
1,00 | |
1,80M | |
53,19 | |
$213,08 | |
$140,11 | |
2,34% | |
-- |
Becton, Dickinson and Co. (BDX) is trading at $183,77 in pre-market trading as of 2026-10-12 09:01:00, up 0,01% ($0,02) from the previous close of $183,75
Pre-market trading shows how investors are pricing BDX before the regular session opens. The current pre-market price is near the previous close, indicating positive early trading sentiment.
Over the past seven days, Becton, Dickinson and Co. (BDX) moved from $178,07 to $183,77, representing a gain of 3,20% ($5,70).
The stock traded between $175,71 and $187,45 during the period. The latest price is near the upper end of the 7-day range, indicating moderate upward.
The average daily volume was 1,70 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 59,8%
BDX is currently trading at $183,77, placing it 59,8% of the way from its 52-week low of $140,11 to its 52-week high of $213,08. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Following the separation of the life science segment, Becton Dickinson operates in four business units. Medical essentials (35% of total sales) includes the legacy medical surgical unit, which sells catheters, syringes, and infection prevention products. Connected care (24%) core products include the Alaris infusion pump, Pyxis dispensing system, and pharmacy automation platforms. Biopharma systems (13%) produces prefillable syringes and autoinjectors. Interventional (29%) is composed of the surgery, peripheral vascular, and urology segments. More than 60% of revenue comes from the United States.
| Industry | SURGICAL & MEDICAL INSTRUMENTS & APPARATUS |
| Employees | 72000 |
| Exchange | NYSE |
| Company Website |
Eligible investors can buy real shares of Becton, Dickinson and Co. (BDX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.